GMJoe™ Consulting | Strategic Intelligence
A federal screening policy changes what a laboratory buys when it makes DNA or RNA in-house.
The instrument can be working perfectly when the experiment falls behind. A laboratory may own the synthesizer, have staff and reagents ready, and still be waiting on a decision made elsewhere.
The White House’s November 5 policy phases in a requirement for recipients and subrecipients of federal life-sciences funding to buy synthetic nucleic acids and benchtop synthesis equipment from suppliers that meet federal screening standards. NIH funds already carried purchasing conditions under the earlier framework. The new policy also specifies what an instrument must do after delivery. In normal connected operation, a run requires authorization from a screener verified by the National Institute of Standards and Technology. NIST is to set the conditions for limited offline operation. (White House policy and NIH grants policy)
The implementation schedule calls for standards on day 90 after release and the first list of qualifying suppliers on day 160. The new purchasing requirement for synthetic nucleic acids takes effect on day 250, followed by the one for equipment on day 340. A research institution can see when its buying rules will change. The standards that will determine what its instruments can rely on are still to come. (Implementation schedule)
Time is what a benchtop instrument was meant to buy. In a filing with the Securities and Exchange Commission, Telesis Bio described the appeal of in-house synthesis in terms of shorter turnaround and greater control over the work. Under the new rules, a laboratory could cut the hours a run takes while losing some control over when it starts. (Telesis Bio filing)
An instrument warranty can cover the machine while a separate company handles screening. If the hardware works and a legitimate request goes unanswered during an outage, who owns recovery? An equipment maker that can take responsibility for restoring authorized operation has something to sell alongside the instrument. A lower-priced competitor might meet the same safety standard and leave the cost of interruption with the laboratory. For the director of a shared facility, that cost can reach several grants whose schedules were built around one instrument.
The policy could also change where synthesis is done. A laboratory that brought work in-house to escape a supplier’s production queue may send some of it back out if a qualifying supplier can offer a firmer delivery date under the same screening regime. In that case, the reliability of screening would help determine how much work stays at the bench, even as the machines themselves get faster.
The first supplier list will tell a research institution where it may buy. The purchasing decision still has to answer who will restore authorized operation when the service is interrupted. Until that responsibility is clear, the capital budget can show an instrument the research schedule cannot count on.
Bring a business problem, question, or opportunity. Joe Cozart applies the Clarity Algorithm™ and delivers a confidential written Clarity Report™ with findings, implications, and practical options.
Joe Cozart, GMJoe™, GMJoe™ Consulting
Private Strategic Engagements — independent, confidential, written strategic assessments for decision-makers confronting consequential uncertainty.
GMJoe™ — Live Upstream.™
Clarity. Strategy. Sovereignty.™